HC Wainwright & Co. Maintains Buy on Belite Bio, Maintains $59 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Belite Bio (NASDAQ:BLTE) and kept the price target at $59.
March 22, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Belite Bio maintained at Buy by HC Wainwright & Co. with a $59 price target.
The reaffirmation of a Buy rating and a high price target by a reputable analyst like Yi Chen suggests a strong confidence in Belite Bio's future performance. This could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100